title: Losing the opportunity to study influenza drugs.
authors.affiliation: Division of Clinical Pharmacology, Johns Hopkins School of Medicine, Osler 501, 600 N Wolfe St, Baltimore, MD 21287, USA. ameyerh1@jhmi.edu
authors.forename: Andrea
authors.initials: A
authors.lastname: Meyerhoff
authors.forename: Paul
authors.initials: P
authors.lastname: Lietman
mesh_terms: D000146:Acids, Carbocyclic; D000998:Antiviral Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003517:Cyclopentanes / Q000627:therapeutic use*; D004196:Disease Outbreaks; D017277:Drug Approval; D006146:Guanidines / Q000627:therapeutic use*; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype; D007251:Influenza, Human / Q000188:drug therapy*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000146:Acids, Carbocyclic; D000998:Antiviral Agents; D003517:Cyclopentanes; D006146:Guanidines; C414210:peramivir